DLBCL lymphoma: what are and what are the possible treatments?
Non-Hodgkin’s lymphoma is a group of cancers of the lymphatic system. About 1,400 new patients with the disease are diagnosed each year, most of them adults. The disease involves lymph nodes, but can appear in any organ in the body. Diffuse Large B Cell (DLBCL) lymphoma is the most common in the non-Hodgkin’s lymphoma group. Dr. Nadav Sarid, director of the Hematology Institute at Wolfson Hospital with the answers

The average age for the onset of DLBCL lymphoma is 65, but it can also occur in young people. This type of lymphoma is an aggressive disease, which is characterized by rapid enlargement of the lymph nodes, and can involve other organs such as the organs of the digestive system. The symptoms are varied, with many patients having general symptoms that include fever, weight loss and night sweats.

Is it possible to cure DLCBL lymphoma?

“Absolutely. Although it is an aggressive disease, in about 60% of cases a complete cure can be achieved with a combination that includes chemotherapy and biological treatment. The success of treatment depends on clinical characteristics such as the patient’s age, functional condition, parameters of disease spread and specific blood tests. “Tumors in the tumor tissue, which predict the chance of treatment success. These genetic tests are available, and have entered the DLBCL treatment routine,” says Dr. Sarid.

Are there any encouraging news lines for DLBCL contestants? What are the future directions for treating the disease presented at the American ASH Hematology Conference? Watch the full excerpt from “Expert’s Word”

It should be emphasized that the choice of possible treatment is for the decision of the therapist who registers the prescription in consultation with the patient. The information As of January 2022. For more information, please contact the attending physician. Service To the public. Served under the auspices of Roche Pharmaceuticals (Israel) Ltd.

By Editor

Leave a Reply